Biotech Values

[genisi]

Does Crispr make RNAi and zinc-finger platform companies less valuable?

Crispr technology does and will make a big change in the academic research world and should become a major tool for genome editing, but I don't think that it makes companies that used other commercially available platforms such as zinc-fingers or TALEns less valuable, not at this time yet. Crispr is considered easier and is obviously faster but each method has restrictions and carries the risk for off-target effects and Crisper has to be further evaluated.